We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > TZLS-501

News List

USPTO grants patent to Tiziana for fully human monoclonal antibody, TZLS-501 expresspharma
August 25, 2020
The grant of this additional patent on TZLS-501 is of significance for the potential treatment of COVID-19 and other pulmonary diseases.
Tiziana Life Sciences signs manufacturing deal with STC Biologics pharmaceutical-technology
July 01, 2020
UK-based biotechnology firm Tiziana Life Sciences has executed an agreement with STC Biologics for the manufacture of TZLS-501 for clinical studies in Covid-19 patients.
Tiziana Developing TZLS-501 as Potential Coronavirus Treatment americanpharmaceuticalreview
March 13, 2020
Tiziana Life Sciences has announced that its TZLS-501 treatment could be a potential treatment for patients infected with coronavirus (COVID-19) who are at risk of respiratory failure.
Tiziana Life Sciences to expedite development of TZLS-501 for COVID-19 expresspharma
March 12, 2020
TZLS-501 is a novel fully human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb) for treatment of patients infected with coronavirus COVID-19.